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Abstract 
Background and aims. Familial hypercholesterolemia (FH) is an inherited disorder characterized 
by high levels of blood cholesterol from birth and premature coronary heart disease. Thus, the 
identification of FH patients is crucial to prevent or delay the onset of cardiovascular events, and 
the availability of a tool helping with the diagnosis in the setting of general medicine is essential to 
improve FH patient identification.  
Methods. This study evaluated the performance of the Dutch Lipid Clinic Network (DLCN) score 
in FH patients enrolled in the LIPIGEN study, an Italian integrated network aimed at improving 
the identification of patients with genetic dyslipidaemias, including FH. 
Results. The DLCN score was applied on a sample of 1377 adults (mean age 42.9±14.2 years) with 
genetic diagnosis of FH, resulting in 28.5% of the sample classified as probable FH and 37.9% as 
classified definite FH. Among these subjects, 43.4% had at least one missing data out of 8, and 
about 10.0% had 4 missing data or more. When analyzed based on the type of missing data, a 
higher percentage of subjects with at least 1 missing data in the clinical history or physical 
examination was classified as possible FH (DLCN score 3-5). We also found that using real or 
estimated pre-treatment LDL-C levels may significantly modify the DLCN score.  
Conclusions. Although the DLCN score is a useful tool for physicians in the diagnosis of FH, it 
may be limited by the complexity to retrieve all the essential information, suggesting a crucial role 
of the clinical judgement in the identification of FH subjects.  
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Introduction 
Familial hypercholesterolaemia (FH) is a monogenic disorder characterized by increased LDL 
cholesterol (LDL-C) levels from birth and increased risk of early coronary heart disease (CHD)1. 
The early identification of FH subjects is therefore essential to reduce the burden of cholesterol and 
prevent or at least delay the occurrence of cardiovascular events. The early initiation of lipid-
lowering therapies in these subjects will reduce morbidity and mortality for premature CHD, and 
will also have an economical return. Unfortunately, FH is an underdiagnosed condition and, as a 
consequence, commonly undertreated until the occurrence of the first cardiovascular event1. 
The diagnosis of FH may be achieved either by targeted screening, aimed at identifying FH cases 
among hypercholesterolemic subjects with personal or family history of premature CHD or 
hypercholesterolemia, or, in alternative, by cascade screening (including genetic testing), aimed at 
identifying first- and second-degree family members of a subject diagnosed with FH. The targeted 
screening approach is cost-effective, but entails the risk of missing 30-60% of affected patients; the 
cascade screening approach guarantees a higher detection rate, although a considerable risk of 
missing affected individuals is still present. These observations have prompted some of the recent 
guidelines to recommend a strategy of universal lipid screening of children1 However, the cost 
effectiveness and utility of universal screening are still undefined. Furthermore, a minority of FH 
patients may have a normal lipid profile at the time of screening, thus facing the risk of missing the 
diagnosis in some people despite screening of the entire population.  
In the context of familial hypercholesterolemia, a relevant question is what to screen — lipids or 
genes? Genetic screening strategy involves searching for mutations in the common genes causing 
FH among suspected subjects and, possibly, their close relatives. It is worth noting that a relevant 
proportion (20-40%) of individuals clinically diagnosed with FH does not present a causative 
mutation in any of the conventionally tested genes. This observation, together with the results of 
genome-wide association studies, showing that the simultaneous presence of a number of single 
nucleotide polymorphisms may significantly influence LDL-C levels (polygenic 
hypercholesterolemia), suggests the possible involvement of variants in multiple genes, each of 
which has a small effect but when in association may increase LDL-C levels at the typical range 
observed in patients with monogenic FH2. In such patients, genetic cascade testing is expected to 
have a very low yield and is unlikely to be cost-effective. Hence, genetic cascade screening is likely 
to benefit only probands where a definite mutation is identified; in others, a strategy of lipid 
profile-based cascade screening may be preferable. 
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FH is clinically diagnosed on the basis of clinical characteristics and laboratory parameters; criteria 
to identify FH subjects include the MEDPED (Make Early Diagnosis to Prevent Early Deaths) 
score3 and the Simon Broome criteria4, based on the LDL-C values and the family clinical history, 
and the Dutch Lipid Clinic Network (DLCN) score, which also includes physical characteristics 
such as tendon xanthomas5 (Supplementary Table 1). The availability of a tool that guides 
diagnosis in the setting of general medicine (or for health professionals not specialized in the 
management of lipid metabolism diseases) is crucial to improve FH patient identification and to 
start the appropriate pharmacological therapy as soon as possible. However, it is not clear whether 
the performance of the available diagnostic scores may efficiently apply to different countries or 
subpopulations (e.g., age groups, mild phenotypes) and how much missing information may 
impact on the diagnosis rate. 
In the present study, we aimed at evaluating the performance of the DLCN score in patients with 
genetic diagnosis of FH enrolled in the LIPIGEN (LIpid TransPort Disorders Italian GEnetic 
Network) network6, addressing the question whether missing information may affect the 
identification of FH subjects. 
 
Methods 
The LIPIGEN is an integrated network aimed at improving the identification of patients with 
genetic dyslipidaemias, including FH, in Italy6. The LIPIGEN-FH study, an observational, 
multicenter, retrospective and prospective study started in 20126, collects data on FH patients 
followed by lipid clinics all over Italy as part of the normal clinical practice. Available information 
includes demographic and clinical data (age, gender, personal and family history of 
hypercholesterolemia or premature cardiovascular or cerebrovascular events, data from physical 
examination), pharmacological therapies and biochemical data. After the visit by a specialized 
physician, patients with clinical suspect of primary hypercholesterolemia are referred for genetic 
testing of the appropriate candidate genes. The decision to address a subject to the genetic testing 
may be based either on the application of the clinical score or on the decision of the lipid specialist, 
supported by anomalies in her/his lipid profile or by the presence of a familial history of 
premature cardiovascular disease (even in the absence of individual increased LDL-C levels, as for 
example in children). The identification of a causative mutation in a patient is then followed by the 
cascade screening of family members to identify new cases of FH, who undergo genetic testing if 
FH is clinically suspected. 
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To test the performance of the DLCN score, the analysis was carried out in all mutation-positive 
patients (as established by genetic test performed in different laboratories), aged 18 years or more, 
who underwent clinical evaluation and had available information on LDL-C levels. The population 
used for this analysis included both FH index cases and the FH relatives identified by cascade 
screening. The DLCN score performance was evaluated also as a function of the number and type 
of missing parameters. In the absence of available pre-therapy LDL-C values (as a part of the 
DLCN score), they were estimated from the actual levels adjusting by correction factors which 
consider the type and dose of current lipid-lowering therapy7. As sensitivity analysis, the 
performance of the DLCN score was evaluated also in a smaller sample of patients (N=343) with 
clinical suspect of FH who have been genetic tested by a centralized laboratory searching for a 
broad range of possible mutations of several candidates genes. For exploratory purposes, the 
DLCN score was applied also on patients aged less than 18 years, in whom the algorithm has not 
been validated. 
Continuous variables are presented as mean±SD, whereas categorical variables are presented as 
cases (n) and percentage rate (%). To define the sensitivity of the DLCN score, the Bayes' theorem 
was applied on the subsample. 
 
Results 
A total of 1,377 mutation-positive adult patients has been included in the present analysis. 
Supplementary table 2 provides the general characteristics of these subjects. The number of men 
and women in the sample was comparable (48.6% vs 51.3% respectively), mean BMI value was 25.5 
(±4.4) Kg/m2, mean glucose level was 90.1 (±18.2) mg/dL. Mean LDL-C, HDL-C, TG levels were 
285.6 (±95.0) mg/dL, 52.8 (±14.3) mg/dL, and 121.4 (±67.4) mg/dL, respectively. Among the subjects 
included in the analysis, 44.2% were on statin therapy. 
When applied to this population with positive genetic test, the DLCN score classified as probable 
FH (score 6-8) 28.5% and as definite FH (score ≥9) 37.9% of subjects; 66.4% had thus a DLCN score 
≥6 and defined as potential FH (Figure 1). Similar results were observed when the DLCN score 
was applied to the subgroup who underwent the genetic testing in a centralized laboratory (29.2% 
and 34.9%, respectively). The presence of variants of uncertain clinical significance was 11.0% 
(DLCN score ≥9), 21.3% (DLCN score 6-8), 31.3% (DLCN score 3-5), and 45.5% (DLCN score 0-2) 
(Supplementary table 3). The Bayes theorem showed that the sensitivity of DLCN test is 0.33. 
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Overall, in our sample, only 56.6% of patients had all the information required to calculate the 
DLCN score through the 8 criteria besides LDL-cholesterol, and about 10.0% had 4 or more 
missing data (Table 1). In particular, among subjects with a DLCN score of 5 (9.2%), just below the 
threshold of the possible diagnosis, about 46.0% had at least one missing criteria information.  
About 34.6% of patients had not information on the presence of tendon xanthoma and/or corneal 
arcus in first-degree relatives and 11.6% and 12.9% had not information on positive history of 
premature coronary heart disease (CHD) or hypercholesterolemia in first-degree relatives, 
respectively. The information on premature CHD or on cerebral/peripheral vascular disease was 
missing in 9.1% and 10.2% of the subjects, respectively (Table 2). The nature of missing 
information had a differential impact on the ability of the DLCN score to identify FH patients. 
Thus, the lack of information related to the family clinical history did not modify the rate of patient 
identification compared with that of subjects without missing data (Table 3); in contrast, the lack of 
information concerning the physical signs typical of FH or the personal history of 
cardio/cerebrovascular events strongly reduced the percentage of subjects classified as definite FH 
(Table 3). 
As for many FH subjects the pre-treatment LDL-C levels were not available, we evaluated whether 
the use of estimated pre-treatment LDL-C levels (adjusting by correction factors considering the 
type and dose of current lipid-lowering therapy) might affect the DLCN score. Patients on statin 
therapy (representing 44.2% of the whole studied population) were grouped based on the 
availability of their pre-treatment LDL-C levels or not (65.2% and 34.8% of the on-statin therapy 
group, respectively) and compared with subjects not on statin therapy. Within the first subgroup, 
26.2% had pre-treatment LDL-C levels >325 mg/dL (Table 4), in line with what observed in patients 
not on statin treatment (22.0%); in contrast, 39.6% of subjects with estimated pre-treatment LDL-C 
value had LDL-C levels ≥325 mg/dL (Table 4). This translated into different percentages of patients 
classified as probable or definite FH by the DLCN score (≥6) (Table 4).  
Finally, when the DLCN score was applied in the mutation-positive paediatric population (<18 
years) in whom the algorithm has not been validated, the diagnosis was unlikely for 29.2% and 
definitive for only 7.5% of children. 
 
Discussion 
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Due to the high burden of cholesterol from birth, patients with FH have a significantly increased 
risk of developing atherosclerosis early in the life and may experience premature coronary heart 
disease. Thus, these patients need to be aggressively and promptly treated to reduce their 
cardiovascular risk. Despite this awareness, FH is largely underdiagnosed in most countries1 and 
frequently the diagnosis of FH is done following a casual biochemical evaluation of LDL-C levels 
or after the occurrence of a premature cardiovascular event. In addition, in most cases FH is 
undertreated, as reported in a study showing that only 48% of FH subjects receive statins8, and 
frequently the dose of statin provided is not adequate to reduce their plasma LDL-C to the levels 
recommended by current guidelines1, 9; finally, statin therapy is often introduced too late in life. 
From all these considerations, it is evident that a timely diagnosis of FH is crucial to start 
immediately with a pharmacological approach integrated with lifestyle modifications, in order to 
reduce the overall cardiovascular risk of FH patients, thus gaining time free of cardiovascular 
events. Therefore, the availability of diagnostic tools that can be widely and easily used by 
physicians may represent a relevant opportunity for the identification of high cardiovascular risk 
patients.  
From our analysis, it is clear that, despite the subjects had a positive genetic test which defined 
their FH condition, the “a posteriori” application of the DLCN score could not classify all of them 
as definite FH. Overall, less than half subjects were classified as definite FH (37.9%).  
Due to its structure, one major limit in the application of the DLCN score is the fact that it derives 
not only from objective information (biochemical evaluation of LDL-C levels and physical 
examination), but also from the personal and family cardiovascular history, which may be more 
difficult to be unbiased. The weight of missing information in the determination of the final score 
is not clear. However, the lack of one or more parameters which are part of the algorithm may 
reduce the final score and may lead to the attribution of an incorrect FH category. This may be of 
particular relevance for those subjects having a DLCN score of 5 and one or more missing data, as 
they might increase their score in the presence of further positive information and thus be shifted 
to the probable or even definite FH category. Obviously, this may affect the possibility of 
addressing the subject to the genetic testing (which is strongly recommended among individuals 
with DLCN score >5) to determine the presence of a causative mutation and may also have an 
impact on the type of pharmacological approach, although this is commonly driven by LDL-C 
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plasma levels and not by genotype. On the other hand, it appears that a large percentage of 
mutation-positive subjects with no missing information would have been classified as unlikely or 
possible FH (35%) by the application of the DUTCH score; despite that, the lipid specialists 
addressed them to the genetic testing on the basis of their specific knowledge about FH, 
recognizing that it is a pathologic condition which may be present with a highly variable 
phenotypes and that a low DUTCH score may be not always suggestive of a negative FH 
condition. This means that the final decision of the lipid specialists is essential to increase the 
detection rate of FH. 
Among subjects with at least 1 missing data, those lacking information on the personal clinical 
history or physical examination were more likely to be categorized in the “possible FH” group 
(54.6% and 40.4%, respectively). In the setting of a new diagnosis, this could lead to an 
underestimation of the individual risk to have FH, and thus may induce the general practitioner 
not to investigate further this possibility and therefore the subject would not be directed to the 
genetic test. Indeed, although the genetic test to detect an underlying molecular defect in an index 
FH patient is costly, it allows early diagnosis, even in childhood, and is carried out once in a 
lifetime; in addition, the FH genetic diagnosis provides a cost-effective tool for cascade testing of 
the FH index case relatives and to prevent premature CHD. As a consequence, also the therapeutic 
strategy adopted might be inadequate to treat this type of patient. Based on these considerations, it 
is evident that the appropriate diagnosis can have a relevant clinical impact.  
Another critical issue concerns the LDL-C levels, as the score should be applied using pre-therapy 
values, while many of the available LDL-C level values are obtained post-statin therapy, and thus 
need to be adjusted based on the drug type and dose. However, this could lead to an 
overestimation of the pre-treatment LDL-C levels10. In our study, we found that, in the group with 
estimated pre-statin LDL-C levels, a higher percentage of subjects had values >325 mg/dL, which, 
by conferring the highest score for this category (Supplementary Table 1), translated into a higher 
percentage of subjects categorized as definite FH compared with the group having measured pre-
statin LDL-C levels.  
It is possible that the DLCN score needs adaptations when applied to populations other than the 
original one. Even more, clinicians should remember that this tool has not been developed for the 
paediatric population. Indeed, when applied to the LIPIGEN paediatric population with positive 
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genetic test for FH, only a small percentage was categorized as definite FH, in line with previous 
observations reporting that these criteria are not valid in children, whereas other criteria might be 
more appropriate as they contain specific cut-off for LDL-C levels in this specific group11. 
From this analysis, it appears obvious that the correct application of the DLCN score requires that 
all the information included in the algorithm must be solicited by the physician during the patient 
visit, to avoid a misclassification and address the right subject to the genetic testing. It is worth 
noting, however, that the less severe phenotypes may not be classified as definite FH, and on the 
other hand, a polygenic form of hypercholesterolemia might be not recognized during a genetic 
testing. We cannot exclude that the low performance of the DLCN score observed in our study 
could be related to the extension of the genetic analysis to the young relatives of the index patients, 
in which the suspect of the disease was suggested basically by lipid levels and by the presence of 
the mutation in the family. This identifies a group of subjects for whom opportunistic screening 
based on clinical algorithms would be ineffective, highlighting the decisive role of cascade 
screening. 
Although the DLCN score is undoubtedly a very useful tool for the physician in the diagnosis of 
FH, in daily practice it could be limited by difficulty in finding information; moreover, it failed to 
identify a third of the subjects with genetic diagnosis of FH. Even if an update of this tool and its 
validation in individual national contexts would be warranted, physicians should be aware that it 
is just a support tool and must rely on their clinical judgment. 
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Figure 1. DLCN score in the mutation-positive group of the LIPIGEN Study 
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Table 1. Number of missing information 
Number of 
missing information 
Distribution 
Frequency Percentages 
Cumulative 
percentages 
0 779 56.57 56.57 
1 209 15.18 71.75 
2 185 13.44 85.19 
3 67 4.87 90.05 
≥4 137 9.95 100.00 
 
13 
Table 2. Missing criteria 
Criteria Missing (%) 
First-degree relative with known premature CHD 11.62 
First-degree relative with known LDL cholesterol >95th percentile 12.85 
First-degree relative with tendon xanthoma and/or corneal arcus 34.57 
Child(ren) <18 years with LDL cholesterol >95th percentile 25.78 
Subject has premature CHD 9.08 
Subject has premature cerebral or peripheral vascular disease 10.17 
Tendon xanthoma 5.37 
Corneal arcus in a person <45 years 11.62 
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Table 3. DLCN score by missing information 
Number of missing 
DLCN score  
Unlikely 
(0-2) 
Possible 
(3-5) 
Probable 
(6-8) 
Definite 
(>8) 
0 missing 5.01% 29.53% 30.55% 34.92% 
At least 1 missing in Group1 (Family history) 5.89% 26.79% 25.89% 41.43% 
At least 1 missing in Group2(Clinical history) 9.79% 54.55% 24.48% 11.19% 
At least 1 missing in Group3 (Physical examination) 9.04% 40.36% 21.08% 29.52% 
Group reference Supplementary Table 1 
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Table 4. LDL-C levels and DLCN score in the mutation-positive sample based on sources of LDL-C 
levels 
  
Total FH 
population 
1377 
Not on statin 
treatment  
(N=768) 
On statin treatment, 
with known  
pre-treatment LDL-C 
levels  
(N=397) 
On statin treatment, 
with estimated  
pre-treatment LDL-C 
levels  
(N=212) 
LDL-C levels 
<155 mg/dL 2.47% 2.60% 1.26% 4.25% 
155-190 mg/dL 6.46% 7.42% 6.30% 3.30% 
191-250 mg/dL 28.40% 28.91% 31.74% 20.28% 
251-325 mg/dL 36.75% 39.06% 34.51% 32.55% 
>325 mg/dL 25.93% 22.01% 26.20% 39.62% 
DLCN score 
Definite >8 37.91% 33.46% 37.53% 54.72% 
Probable 6-8 28.47% 27.47% 30.98% 27.36% 
Possible 3-5 28.32% 31.90% 28.72% 14.62% 
Unlikely <3 5.30% 7.16% 2.77% 3.30% 
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Supplementary table 1. Dutch Lipid Clinic Network score criteria 
 Points 
Group 1: family history 
First-degree relative with known premature (<55 years, men; <60 years, 
women) coronary heart disease (CHD) 
OR 
First-degree relative with known LDL cholesterol >95th percentile by 
age and gender for country 
1 
First-degree relative with tendon xanthoma and/or corneal arcus 
OR 
Child(ren) <18 years with LDL cholesterol >95th percentile by age and 
gender for country 
2 
Group 2: clinical history 
Subject has premature (<55 years, men; <60 years, women) CHD 2 
Subject has premature (<55 years, men; <60 years, women) cerebral or 
peripheral vascular disease 
1 
Group 3: physical examination 
Tendon xanthoma 6 
Corneal arcus in a person <45 years 4 
Group 4: biochemical results (pre-treatment LDL-C ) 
>8.5 mmol/L (>325 mg/dL) 8 
6.5–8.4 mmol/L (251–325 mg/dL) 5 
5.0–6.4 mmol/L (191–250 mg/dL) 3 
4.0–4.9 mmol/L (155–190 mg/dL) 1 
 
Supplementary table 2. Characteristics of mutation-positive patients of the LIPIGEN study 
Age at visit, mean (SD) N valid 1154 42.9 (14.2) 
Male (%)  N valid 1375 669 (48.6) 
BMI (Kg/m2), mean(SD) N valid 1190 25.5 (4.4) 
LDL-cholesterol (mg/dL), mean(SD) N valid 1377 285.5 (95.0) 
Total cholesterol (mg/dL), mean(SD) N valid 1366 324.3 (100.1) 
Triglycerides (mg/dL), mean(SD) N valid 1362 121.4 (67.4) 
HDL cholesterol (mg/dL), mean(SD) N valid 1367 52.8 (14.3) 
Lp(a) (mg/dL), mean(SD) N valid 171 39.6 (89.3) 
Glucose (mg/dL), mean(SD) N valid 922 90.1 (18.2) 
Statin Therapy (%) N valid 1377 609 (44.2) 
 
Supplementary table 3. Pathogenicity of variants among DLCN score classes. I: pathogenic 
variant; II likely pathogenic variant; III: variant of unknown clinical significance. 
FH diagnosis with DLCN score 
Pathogenicity 
I II III Total 
Definite (>8) 
43 
(58.90%) 
 
22 
(30.14%) 
 
8 
(10.96%) 
 
73 
 
 
Probable (6-8) 
32 
(52.46%) 
 
16 
(26.23%) 
 
13 
(21.31%) 
 
61 
 
 
Possible (3-5) 
27 
(42.19%) 
 
17 
(26.56%) 
 
20 
(31.25%) 
 
64 
 
 
Unlikely (0-2) 
2 
(18.18%) 
 
4 
(36.36%) 
 
5 
(45.45%) 
 
11 
 
 
Total 104 
 
59 
 
46 
 
209 
 
 
